79 results
8-K
EX-1.1
ITCI
Intra-Cellular Therapies Inc
18 Apr 24
Entry into a Material Definitive Agreement
5:25pm
jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation … liability under or relating to, or actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any Release
S-3ASR
EX-4.11
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Automatic shelf registration
4:01pm
conferred upon it by this Indenture;
The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution … or liabilities likely to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee
S-3ASR
EX-4.10
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Automatic shelf registration
4:01pm
it by this Indenture;
The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement … to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security
8-K
EX-1.1
8e2m16cadh1c
5 Jan 22
Entry into a Material Definitive Agreement
5:06pm
8-K
EX-10.1
y765zo h47h1biapmt
5 Jan 22
Financial Statements and Exhibits
4:58pm
424B5
cuw4sc7r
5 Jan 22
Prospectus supplement for primary offering
4:51pm
424B5
azmbmp84yq 9qk4dd
3 Jan 22
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
ai8yc82nrz0
3 May 21
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
7:42am
8-K
EX-99.1
firbnui cxm13dm19yxz
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am
8-K
EX-1.1
4wtq qm4n
11 Sep 20
Entry into a Material Definitive Agreement
4:47pm
424B5
p6qv0vj
11 Sep 20
Prospectus supplement for primary offering
4:44pm
8-K
EX-99.2
21gkvr3
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
424B5
1p34duko6 q4p0
9 Sep 20
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
16sbxl 069b47hvzo
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am